Ozempic Maker Advances False Ad Suit Against Compound Pharmacy

Novo Nordisk A/S can move forward with a lawsuit against a compound pharmacy that allegedly falsely advertised its weight-loss products as equivalent to generic versions of Ozempic, Wegovy, and Rybelsus, a federal judge said.

The brand-name drugmaker’s claims that defendant Liferxmd’s ads caused consumer confusion, led to a loss of goodwill, and harmed its reputation demonstrated it was sufficiently injured to satisfy constitutional and Lanham Act prerequisites for bringing the suit, Judge Michael A. Shipp of the US District Court for the District of New Jersey said Wednesday. Shipp refused to dismiss the case, saying in an unpublished decision that ...